AC Immune
ACIU
37 hedge funds and large institutions have $85.7M invested in AC Immune in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
81% more call options, than puts
Call options by funds: $292K | Put options by funds: $161K
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
16% more funds holding
Funds holding: 32 → 37 (+5)
2.6% less ownership
Funds ownership: 31.79% → 29.2% (-2.6%)
45% less capital invested
Capital invested by funds: $157M → $85.7M (-$71.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$444K |
| 2 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$421K |
| 3 |
Renaissance Technologies
New York
|
+$352K |
| 4 |
SM
Scoggin Management
New York
|
+$303K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$218K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$7.64M |
| 2 |
SC
Stempoint Capital
New York
|
-$2.17M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$1.51M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$104K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$76.5K |
ACIU Hedge Fund Activity: Q1 2024 in Review
37 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in AC Immune (ACIU) for Q1 2024, worth a combined $85.7M — down 45% from $157M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ACIU positions and 5 closed out — a net gain of 5 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $444K. The largest seller was Morgan Stanley, cutting an estimated $7.64M.
- 37 institutional investors held AC Immune (ACIU) as of Q1 2024, up from 32 in Q4 2023.
- Funds reported $85.7M of AC Immune stock for Q1 2024, down 45% quarter-over-quarter.
- 10 funds opened new AC Immune positions in Q1 2024 and 5 closed out, a net change of +5 holders.
- The largest AC Immune buyer in Q1 2024 was BlackRock, an estimated $444K added.
- The largest AC Immune seller in Q1 2024 was Morgan Stanley, an estimated $7.64M sold.
Based on aggregated 13F filings for Q1 2024.